Vir Biotechnology, Inc. Accrued Liabilities and Other Liabilities
Vir Biotechnology, Inc. (VIR) had Accrued Liabilities and Other Liabilities of $77.21 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedLiabilitiesAndOtherLiabilities · last filed 2026-08-05
- 2026-06-30: Accrued Liabilities and Other Liabilities $77.21M.
- 2026-03-31: Accrued Liabilities and Other Liabilities $68.11M.
- 2025-12-31: Accrued Liabilities and Other Liabilities $83.01M.
- 2025-09-30: Accrued Liabilities and Other Liabilities $68.38M.
| Period end | Accrued Liabilities and Other Liabilities | Accrued Liabilities and Other Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $77.21M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $68.11M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $83.01M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $68.38M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $82.66M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $104.13M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $98.52M 10-K · filed 2026-02-23 | $85.87M 10-K · filed 2025-02-27 |
| 2024-09-30 | $94.66M 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $75.32M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $72.26M 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $104.22M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $146.11M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $197.58M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $455.92M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $489.09M 10-K · filed 2024-02-26 | |
| 2022-09-30 | $282.62M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $354.09M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $577.67M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $236.51M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $64.84M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $64.07M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $70.07M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $76.94M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $44.34M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $38.56M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $21.92M 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $26.50M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |